Complete percutaneous myocardial revascularization in patients with STEMI complicated by cardiogenic shock

  • Milovan Petrovic University of Novi Sad, Medical faculty
  • Milana Jarakovic
  • Milenko Cankovic
  • Ilija Srdanovic
  • Mila Kovacevic
  • Dragica Tesic
  • Vladimir Ivanovic
  • Aleksandar Redzek
  • Lazar Velicki
Keywords: myocardial infarction, shock, cardiogenic, myocardial revascularization, percutaneous coronary intervention, mortality

Abstract


Abstract

 

Background/Aim. Despite considerable progress in terms of early myocardial revascularization and the use of mechanical circulatory support, cardiogenic shock continues to be the leading cause of death in acute myocardial infarction. The current recommendations of the European Society of Cardiology advocate early revascularization of all critical stenosis or highly unstable lesions in the state of cardiogenic shock, while recently published studies favour the early revascularization of the infarct related artery only, in patients with acute myocardial infarction with the ST segment elevation (STEMI) presenting with cardiogenic shock. The aim of the study was to assess the impact of the complete early percutaneous myocardial revascularization in an acute myocardial infarction complicated by cardiogenic shock on intra-hospital mortality. Methods. The research was conducted as a retrospective observational analysis of data obtained from the hospital registry for cardiogenic shock. The study group consisted of 235 patients treated in the period from August 2007 until October 2016 for STEMI complicated by cardiogenic shock. Three groups were formed. The first group consisted of patients with one vessel disease who underwent revascularization of infarct related artery; the second group of patients had multi-vessel disease and only culprit lesions were revascularized and the third one consisted of patients with multi-vessel disease and the complete myocardial revascularization performed. Additional subgroups were formed in reference to the intra-aortic balloon pump (IABP) implantation. Intra-hospital mortality was analyzed in all groups and subgroups. Results. Revascularization of the culprit lesion alone among patients with multi-vessel disease was performed in 142 (60.4%) patients while the complete revascularization (revascularization of “culprit” and other significant lesions) was performed in 28 (11.9%) patients with multi-vessel disease. There were 65 (27.7%) patients with single-vessel disease who underwent revascularization of infarct related artery. The lowest mortality was found in the group of patients with multi-vessel coronary disease who underwent complete myocardial revascularization and had IABP implanted (mortality was 35.7%). The difference in the mean value of the left ventricular ejection fraction (EF) between the surviving and deceased patients was statistically significant (< 0.005). The average EF of survivors was 44% (35%–50%) while 30% (25%–39.5%) deceased of patients. Based on the obtained data, the mathematically predictive model was tested. The receiver operating characteristic (ROC) curve showed that our model is a good predictor of fatal outcome (p < 0.0005; AUROC = 0.766) with the sensitivity of 80.3%, and the specificity of 67%. Conclusion. STEMI complicated by cardiogenic shock is still associated with a high mortality rate. Complete myocardial revascularization independently as well as in combination with an IABP, significantly reduces mortality in patients with acute STEMI complicated by cardiogenic shock.

 

References

REFERENCES

Vincent LJ, DeBacker D. Circulatory shock. N Engl J Med 2013; 369(18): 1726–34.

Windecker S, Kohl P, Alfonso F, Collet JP, Cremer J, Falk V, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization:a report of the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014; 35(37): 2541–619.

Lindholm MG, Køber L, Boesgaard S, Torp-Pedersen C, Aldershvile J. Trandolapril Cardiac Evaluation study group. Cardiogenic shock complicating acute myocardial infarction; prognostic impact of early and late shock development. Eur Heart J 2003; 24(3): 258–65.

Goldberg RJ, Spencer FA, Gore JM, Lessard D, Yarzebski J. Thirty-Year Trends (1975 to 2005) in the Magnitude of, Management of, and Hospital Death Rates Associated With Cardiogenic Shock in Patients With Acute Myocardial Infarction A Population-Based Perspective. Circulation 2009; 119(9): 1211–19.

Goldberg RJ, Samad NA, Yarzebski J, Gurwitz J, Bigelow C, Gore JM. Temporal trends (1975–1997) in the incidence and hospital death rates of cardiogenic shock complicating acute myocardial infarction (Worcester Heart Attack Study). N Engl J Med 1999; 340(15): 1162–68.

Leor J, Goldbourt U, Reicher-Reiss H, Kaplinsky E, Behar S. Cardiogenic shock complicating acute myocardial infarction in patients without heart failure on admission: incidence, risk factors, and outcome. Am J Med 1993; 94(3): 265–73.

Babaev A, Frederick PD, Pasta DJ, Every N, Sichrovsky T, Hochman JS. NRMI Investigators. Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. JAMA 2005; 294(4): 448–54.

Alexander JH, Reynolds HR, Stebbins AL, Dzavik V, Harrington RA, Van de Werf F, et al. Effect of tilarginine acetate in pa-tients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA 2007; 297(15): 1657–66.

Feitosa Filho FH, Conejo F, Nunes dos Santos L, Campos CA, Neto PAL. In-hospital Outcomes of Patients with Cardiogenic Shock due to ST-Segment Elevation Myocardial Infarction. Rev Bras Cardiol Invasiva 2013; 21(3): 265-9.

Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci K, Bueno H, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 39(2): 119–77.

Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. J Am Coll Cardiol 2016; 67(10): 1235–50.

Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Lo-scalzo J. Harrison’s Principles of Internal Medicine. 18th ed. New York, NY: McGraw-Hill; 2012.

Bonnow RO, Mann DL, Zipes DP, Libby P. Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine. 9th ed. Philadelphia: Elsevier Science; 2011.

Kolte D, Khera S, Aronow WS, Mujib M, Palaniswamy C, Sule S, et al. Trends in incidence, management, and outcomes of cardiogenic shock complicating ST-elevation myocardial infarction in the United States. J Am Heart Assoc 2014; 3(1): e000590.

Menon V, Fincke R. Cardiogenic shock: a summary of the ran-domized SHOCK trial. Congest Heart Fail 2003; 9(1): 35–9.

Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, et al. Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial. Lancet 2013; 382(9905): 1638–45.

Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, et al. Intraaortic Balloon Support for Myocardial Infarction with Cardiogenic Shock. N Engl J Med 2012; 367(14): 1287–96.

Institute of Public Health of Serbia “Dr Milan Jovanović Batut”. Inci-dence and mortality of acute coronary syndrome in Serbia. In: Serbian Acute Coronary Syndrome Registry: Report No. 10. Belgrade: Institute of Public Health of Serbia Dr Milan Jova-novic Batut; 2015.

Garcia-Alvarez A, Arzamendi D, Loma-Osorio P, Kiamco R, Masotti M, Sionis A, et al. Early risk stratification of patients with cardiogenic shock complicating acute myocardial infarction who undergo percutaneous coronary intervention. Am J Cardiol 2009; 103(8): 1073–7.

Rasoul S, Ottervanger JP, De Boer MJ, Dambrink JH, Hoorntje JC, Marcel Gosselink AT, et al. Zwolle Myocardial Infarction Study Group. Predictors of 30-day and 1-year mortality after primary percutaneous coronary intervention for ST-elevation myocardial infarction. Coron Artery Dis 2009; 20(6): 415–21.

Toma M, Buller CE, Westerhout CM, Fu Y, O’Neill WW, Holmes DR, et al. APEX-AMI Investigators. Non-culprit coronary ar-tery percutaneous coronary intervention during acute ST-segment elevation myocardial infarction: insights from the APEX-AMI trial. Eur Heart J 2010; 31(14): 1701–7.

Sorajja P, Gersh BJ, Cox DA, McLaughlin MG, Zimetbaum P, Costantini C, et al. Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial in-farction. Eur Heart J 2007; 28(14): 1709–16.

Ibrahim H, Sharma PK, Cohen DJ, Fonarow GC, Kaltenbach LA, Effron MB, et al. Multivessel Versus Culprit Vessel-Only Percutaneous Coronary Intervention Among Patients With Acute Myocardial Infarction: Insights From the TRANSLATE-ACS Observational Study. J Am Heart Assoc 2017; 6(10): pii: e006343.

Wald DS, Morris JK, Wald NJ, Chase AJ, Edwards RJ, Hughes LO, et al. PRAMI Investigators. Randomised trial of preven-tive angioplasty in myocardial infarction. N Engl J Med 2013; 369(12): 1115-23.

Gershlick AH, Khan JN, Kelly DJ, Greenwood JP, Sasikaran T, Curzen N, et al. Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percuta-neous coronary intervention for STEMI and multivessel dis-ease: the CvLPRIT trial. J Am Coll Cardiol 2015; 65(10): 963-72.

Thiele H, Akin I, Sandri M, Fuernau G, de Waha S, Meyer-Saraei R, et al. PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock. N Engl J Med. 2017; 377(25): 2419–32

Thiele H, Allam B, Chatellier G, Schuler G, Lafont A. Shock in acute myocardial infarction: the Cape Horn for trials? Eur Heart J. 2010; 31(15): 1828-35.

Mehta RH, Ou FS, Peterson ED, Shaw RE, Hillegass WB Jr, Rumsfeld JS, et al. American College of Cardiology-National Cardiovascular Database Registry Investigators. Clinical significance of post-procedural TIMI flow in patients with cardiogenic shock undergoing primary percutaneous coronary intervention. JACC Cardiovasc Interv 2009; 2(1): 56–64

Published
2021/02/11
Section
Original Paper